India's Pharmaceutical Future: Generics Remain King Through 2030
During a significant panel discussion in Hyderabad focusing on the pharmaceutical sector's next growth phase, industry leaders projected that India's pharmaceutical industry will continue to be anchored in generics and biosimilars through the year 2030. This outlook persists even as companies are steadily expanding their portfolios into more complex areas like biologics, specialized services, and capability-driven business models.
The Enduring Role of Generics
GV Prasad, Co-Chairman and Managing Director of Dr. Reddy's Laboratories, emphasized that India continues to function as the "generic pharmacy of the world." He noted that innovation within the sector is still in an evolutionary stage. Prasad clarified that while the near-term product mix will overwhelmingly be dominated by generics and biosimilars, the coming years should witness a gradual but steady growth in biologics. Furthermore, he highlighted an expansion into services and capabilities that move the industry beyond pure cost-based competition.
The Call for a Strategic Shift
Shreehas Tambe, Managing Director and CEO of Biocon Biologics, presented a compelling argument for India to urgently shift its strategic focus. He advocated moving from a position of cost leadership to one of capability leadership. Tambe acknowledged that the country possesses the necessary talent base and policy intent to support this innovative transition. However, he stressed that building a durable and self-sustaining innovation ecosystem will require three critical elements:
- Significant patience and long-term vision
- Access to long-term, patient capital
- Deeper, more meaningful collaboration between academia and industry
Technology as a Catalyst for Change
The discussion prominently featured Artificial Intelligence (AI) as a potential accelerator for this industry-wide transition. Panelist Winselow Tucker drew a powerful comparison, likening AI's potential impact on drug development to India's historic leap in the telecommunications sector. He explained that AI-driven research and development could dramatically compress drug development timelines, substantially reduce associated costs, and ultimately make true innovation more attainable for Indian companies over the next decade.
The Evolving Role of Global Capability Centers
From a multinational corporation perspective, Eric Mansion provided insights into the evolving role of India-based Global Capability Centres (GCCs). He observed that these centers are progressively moving beyond their traditional role of low-cost service delivery. They are now taking on more sophisticated roles that include providing specialized expertise and contributing to early-stage innovation. Mansion identified key factors for success:
- Execution speed and operational agility
- The ability to deploy AI technologies at scale
- Supportive and predictable government regulation
- The adoption of value-based pricing models in the market
Addressing Structural and Policy Constraints
Panelists did not shy away from discussing the significant structural constraints facing the industry, with funding being a primary concern. Stefan Miltenyi pointed out that significantly higher levels of research funding are imperative. He also called for faster and more predictable regulatory processes to help retain global scientific talent and enable breakthrough science within India. Miltenyi issued a warning, stating that current funding levels combined with regulatory uncertainty can severely slow progress and weaken the global competitiveness of the Indian pharmaceutical sector.
On the policy front, participants welcomed recent initiatives by the Indian government in biosciences and clinical research. However, they unanimously stressed that a strong, vibrant domestic market that actively rewards and values innovation is absolutely essential for long-term success. The experience of China was cited as an instructive lesson in long-term strategic planning and fast-follower innovation models. Despite this, speakers cautioned against any attempt to blindly replicate China's model, emphasizing the need to thoughtfully adapt such strategies to India's unique economic, social, and regulatory context.
